Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 13/20 | 0.39 |
| ▸ | CCL5 | P13501 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935264 | 0.91 | CCR5 (0.39) | CCR5CCL5 | |
| SCHEMBL4691489 | 0.85 | CCR5 (0.43) | CCR5CCL5KCNH2HCRTR2HCRTR1 | |
| SCHEMBL4696229 | 0.85 | CCR5 (0.42) | CCR5CCL5KCNH2HCRTR2HCRTR1 | |
| SCHEMBL4969362 | 0.82 | CCR5 (0.48) | CCR5CCL5KCNH2HCRTR2HCRTR1 | |
| SCHEMBL4697962 | 0.81 | CCR5 (0.43) | CCR5CCL5KCNH2HCRTR2HCRTR1 | |
| SCHEMBL5660545 | 0.80 | CCR5 (0.41) | CCR5CCL5 | |
| SCHEMBL4693713 | 0.80 | CCR5 (0.49) | CCR5CCL5HCRTR2HCRTR1 | |
| SCHEMBL4693570 | 0.79 | CCR5 (0.52) | CCR5CCL5KCNH2 | |
| SCHEMBL3286468 | 0.79 | CCR5 (0.52) | CCR5CCL5KCNH2 | |
| SCHEMBL5662861 | 0.79 | CCR5 (0.38) | CCR5CCL5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | CCR5 1/4885CCL5 14/4885KCNH2 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.